Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis (Q43744352)

26 November 2017

0 references

Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis (English)

1 reference

26 November 2017

0 references

1 reference

1 reference

1 reference

2

1 reference

26 November 2017

Whitsel EA

1

1 reference

26 November 2017

Matsumoto AM

series ordinal

3

1 reference

26 November 2017

Anawalt BD

series ordinal

4

1 reference

26 November 2017

Siscovick DS

series ordinal

5

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

American Journal of Medicine

26 November 2017

1 reference

26 November 2017

111

1 reference

26 November 2017

4

1 reference

26 November 2017

261-269

1 reference

Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Sample size nomograms for interpreting negative clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Surrogate end points in clinical trials: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Quantitative synthesis in systematic reviews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Randomized clinical trial of testosterone replacement therapy in hypogonadal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. Correlation with plasma testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Increase in hepatic lipase activity after testosterone substitution in men with hypogonadism of pituitary origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Treatment of male hypogonadism with testosterone enanthate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Relationship of high density lipoprotein cholesterol with total and free testosterone and sex hormone binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Relation between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Serum high density lipoprotein subclasses, testosterone and sex-hormone-binding globulin in Trinidadian men of African and Indian descent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Effect of sex hormones on protamine inactivated and resistant postheparin plasma lipases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Diurnal testosterone levels in peripheral plasma of human male subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Decrease in high density lipoprotein cholesterol during prolonged storage. CELL Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Publication bias and clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Publication bias in clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Testosterone decreases lipoprotein(a) in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Usefulness of sex steroid hormone levels in predicting coronary artery disease in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900833-6

10.1016/S0002-9343(01)00833-6

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference